ImmunityBio's ANKTIVA Receives EU Authorization for Bladder Cancer, Expanding Global Access
IBRX has more than doubled off its 52-week low of $1.83.
Summary
ImmunityBio announced European Commission authorization for ANKTIVA with BCG for non-muscle invasive bladder cancer, significantly expanding its market reach to 33 countries and addressing a critical unmet medical need.
Key Events · Product Development and Regulatory · IBRX
-
EU Marketing Authorization Granted
The European Commission has granted conditional marketing authorization for ANKTIVA® (nogapendekin alfa inbakicept) in combination with BCG for adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ.
-
Expanded Global Access to 33 Countries
This authorization expands ANKTIVA's global access to 33 countries, including all 27 European Union member states plus Iceland, Norway, and Liechtenstein, establishing a broad commercial footprint in under two years from initial U.S. FDA approval.
-
First Immunotherapy for Indication in Europe
ANKTIVA plus BCG is the first immunotherapy to receive marketing authorization in Europe for this NMIBC indication, addressing a significant unmet medical need where no authorized treatment previously existed.
-
Strong Clinical Efficacy
The conditional authorization is supported by results from the QUILT-3.032 study, demonstrating a 71% complete response rate and a median duration of complete response of 26.6 months.
Analysis · IBRX · Life Sciences
ImmunityBio has achieved a critical regulatory milestone with the European Commission's conditional marketing authorization for ANKTIVA with BCG. This approval significantly expands the commercial footprint of ANKTIVA to 33 countries, including all EU member states, and positions it as the first authorized immunotherapy in Europe for BCG-unresponsive non-muscle invasive bladder cancer. This addresses a substantial unmet medical need, as patients previously faced radical cystectomy as the primary alternative. The authorization, based on strong clinical data showing a 71% complete response rate, is a major positive catalyst for the company's revenue potential and global market penetration.
At the time of this filing, IBRX was trading at $6.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.9B. The 52-week trading range was $1.83 to $8.28. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.